Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers

Abstract

Purpose: The chromosomal radiosensitivity of a selected group of familial breast cancer patients carrying a mutation in BRCA1 (n=11) or BRCA2 (n=9) and a group of healthy mutation carriers (n=12) was investigated and compared to a reference group of breast cancer patients without a BRCA1/2 mutation (n=78) and a group of healthy women carrying no mutation (n=58).Materials and methods: The chromosomal radiosensitivity was assessed with the G2 and the G0‐micronucleus (MN)‐assay on fresh blood samples and on Epstein‐Barr virus (EBV)‐transformed lymphoblastoid cell lines. For the MN‐assay, lymphocytes were exposed in vitro to 3.5 Gy and 2 Gy 60Co γ‐rays at a high dose rate (HDR) or low dose rate (LDR). 70‐h post‐irradiation cultures were arrested and micronuclei were scored in 1000 binucleate cells. For the G2‐assay lymphocytes were irradiated in vitro with a dose of 0.4 Gy 60Co γ‐rays after 71h incubation. Cultures were arrested 90 min after irradiation and chromatid breaks were scored in 50 metaphases.Results: The group of breast cancer patients with a BRCA1 or 2 mutation was on average more radiosensitive than the control group, but not different from breast cancer patients without a BRCA mutation. The radiation response of healthy BRCA1/2 carriers was not significantly different from the control group and also not different from relatives without a BRCA mutation. Comparing the radiation response in EBV cell lines derived from breast cancer patients with or without a BRCA1 mutation revealed no significant difference. Conclusions: Our results reveal that chromosomal radiosensitivity observed in breast cancer patients heterozygous for BRCA1 or 2 mutations, could not be demonstrated in healthy BRCA1/2 mutation carriers. This suggests that mutations in BRCA1 or 2 genes are not playing a main role in chromosomal radiosensitivity, this although BRCA1 and 2 are both involved in DNA repair/signalling processes.